Hormonal
Combining extended dosing intervals (e.g., every two weeks) with increased dose sizes (e.g., doubling the mg strength) can maintain nearly 100% of the weight loss efficacy while halving the cost.
If you are on a lower dose of a GLP-1 drug (like 5mg tirzepatide) and find the weekly cost prohibitive, ask your doctor about switching to a higher dose (like 10mg or 15mg) taken every two weeks. This strategy can keep your weight loss results nearly identical to taking the lower dose weekly, but at half the cost. This is only possible if your body can handle the higher individual dose without excessive side effects.
if the decrease in dose frequency involves an appropriate increase in dose size, then approximately 100% of the weight loss is maintained.
Why this rating
Based on mathematical modeling and simulation, not direct clinical trials for these specific combined regimens.
Source
Alternative dosing regimens of <scp>GLP</scp> ‐1 receptor agonists may reduce costs and maintain weight loss efficacy
Anıl Cengiz et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16229
More from this paper
- Extending the dosing interval of GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) from once-weekly to once-every-two-weeks reduces medication costs by approximately 50% while maintaining 70-75% of the weight loss efficacy.Limited
- At a population level, distributing GLP-1 medications using extended dosing intervals (q2wk) allows twice as many obese adults to be treated for the same total cost, leading to greater reductions in national obesity rates and mortality.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →